In a manuscript gently entitled “Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving to a personalized approach?”23, they cite “challenging inconsistencies” in trials of HFpEF: indeed. Here, NR3C2 is linked to heart failure.